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 Abstract 
Objective 
To examine the effect of an oral prenatal probiotic on group B Streptococcus (GBS) colonization and to 
demonstrate the feasibility of a larger randomized controlled trial. 
 
Design 
This pilot study was an open-label, two-group quasi-experiment. 
 
Setting 
An urban central city nurse-midwifery and wellness center serving a diverse population. 
 
Participants 
Ten pregnant participants received the oral probiotic (Florajen3) taken once daily, and 10 participants served as 
controls. 
 
Methods 
A questionnaire on dietary practices, vaginal cleansing, sexual history, and symptoms and GBS colony count 
samples were taken at 28-, 32-, and 36-weeks gestation. 
 
Results 
Participants in the probiotic group reported no adverse events or minor side effects; one half reported improved 
gastrointestinal symptoms. Although two women in each group had positive qualitative prenatal GBS cultures at 
36 weeks, the probiotic group participants had lower quantitative GBS colony counts. The eight GBS negative 
averaged 90% probiotic adherence compared with two GBS positive women who averaged 68%. Yogurt 
ingestion was inversely related (p= .02) to GBS colonization. 
 
Conclusions 
Prenatal probiotic therapy has the potential to reduce GBS colonization. The potential of the probiotic 
intervention appears to be linked to daily adherence. A controlled clinical trial with a larger, adequately powered 
sample is feasible and justified. 
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Introduction 
Normal bacterial flora such as Bifidobacterium species make up more than 90% of normal colon microflora and 
are widely regarded as markers of gut and immune health (Centers for Disease Control and Prevention [CDC], 
2002, 2010; Fooks & Gibson, 2002). The bacterial environment can be enhanced through probiotic bacteria 
supplementation. Probiotics are considered a food supplement and are generally regarded as safe because they 
are not systemically absorbed in healthy individuals (Elias, Bozzo, & Einarson, 2011). They confer health benefits 
on the host through a number of mechanisms, including maintaining homeostasis of gut bacteria, acidifying 
mucosal surfaces, and preventing pathogen adherence (Food and Agriculture Organization of the United Nations 
and World Health Organization [FAO/WHO], 2001). Probiotics must survive the acidic human gastrointestinal 
tract and adhere to the gut mucosa (FAO/WHO, 2002). Multispecies probiotic supplements may be beneficial 
due to synergies that enhance healthy colonization on mucosal surfaces (Kim et al., 2006). 
 
Vaginal Flora and Probiotic Interventions 
Independent of hygiene, most vaginal bacteria originate and ascend from intestinal microbes (Bolton, Van Der 
Straten, & Cohen, 2008). The predominance of Lactobacillus is the marker for healthy vaginal flora and can be 
identified on microscopic examination of vaginal secretions (Donders, 1999). There have been a number of 
studies of women's health applications of probiotics because vaginal flora can be modified through the use of 
probiotic supplements (Abad & Safdar, 2009). The authors of a meta-analysis concluded that oral probiotics can 
treat bacterial vaginosis, though efficacy against candidiasis or cystitis was not demonstrated (Abad & Safdar, 
2009). 
 
Midwives suggest probiotics as a safe, nonpharmacologic strategy to prevent group B Streptococcus infection, 
although this clinical approach had not been scientifically studied previously. 
 
Prenatal Probiotics 
The authors of an integrative review of the literature documented that a variety of probiotics have been 
administered during clinical trials that included more than 2,000 pregnant experimental group participants who 
resided in mostly European countries with no reports of side effects or negative sequelae (VandeVusse, Hanson, 
& Safdar, 2013). Prenatal probiotics significantly reduce the risk of atopy in offspring (West & Prescott, 2013); 
however, more research specific to maternal and neonatal outcomes is needed. 
 
Probiotic Actions against Group B Streptococcus (GBS) 
Midwives have suggested probiotics as a safe, nonpharmacologic strategy to prevent GBS infection (Singleton, 
2007), though this clinical approach had not yet been examined scientifically at the time of our study. 
Lactobacillus predominance in vaginal flora was associated with reduced GBS colonization in two studies. In a 
randomized controlled trial (RCT) of 191 nonpregnant women, a perineal topical probiotic intervention 
decreased GBS in vaginal flora (Ronnqvist, Forsgren-Brusk, & Hakansson, 2006). An analysis of the vaginal flora 
of 201 pregnant Iranian women (who did not receive a probiotic intervention) revealed that 12% were GBS 
colonized and that Lactobacillus was inversely related to GBS colonization (Moghaddam, 2010). 
 
In vitro testing demonstrated that the live culture, freeze-dried, probiotic combination Florajen3 ( > 7.5 x109 L. 
acidophillus, > 6.0 x109 .B. lactis, and > 1.5 x109 B. longum) inhibits GBS when they are cultured together 
independent of lactic acid production (Ephraim et al., 2012). Florajen3 had good adherence to epithelial cells in 
cell culture and resulted in a significant drop in the pH (Ephraim et al., 2012). These findings suggested that 
Florajen3 administered prenatally has the potential to reduce GBS colonization in vivo. 
 
Prenatal GBS Colonization 
GBS causes the most prevalent perinatal infection, and GBS colonization of the vaginal and gastrointestinal 
tracts is transient (Kubota, Nojima, & Itoh, 2002), with rates in the range of 10% to 30% with higher percentages 
among African Americans (Hickmann, Rench, Ferrieri, & Baker, 1999). GBS is transferred to the neonate during 
the birth process through contact with the birth canal (CDC, 2010). Neonates exposed to GBS are at risk for 
acquiring early-onset group B Streptococcus disease (EOGBSD), which has a significant mortality rate of 5% to 
10% (CDC 2010). The rates of EOGBSD vary by continent according to the United Kingdom National Screening 
Committee (UK NSC; 2012). The lowest average rate of EOGBSD per 1,000 live births was reported in Southeast 
Asia (0.11) with higher rates reported in Africa (0.53), Europe (0.45), and the Americas (0.50). Internationally, 
there is variation in approaches to EOGBSD prevention. In some countries such as the United Kingdom, a risk-
based approach is used to determine candidates for intrapartum antibiotic prophylaxis (IAP) (UK NSC, 2012), 
whereas in other countries, prenatal screening and risk factors are combined to determine the need for IAP 
(Association of Ontario Midwives, 2010). 
 
Prevention Guidelines for EOGBSD 
GBS causes the most prevalent perinatal infection, and GBS colonization of the vaginal and gastrointestinal 
tracts is transient (Kubota, Nojima, & Itoh, 2002), with rates in the range of 10% to 30% with higher percentages 
among African Americans (Hickmann, Rench, Ferrieri, & Baker, 1999). GBS is transferred to the neonate during 
the birth process through contact with the birth canal (CDC, 2010). Neonates exposed to GBS are at risk for 
acquiring early-onset group B Streptococcus disease (EOGBSD), which has a significant mortality rate of 5% to 
10% (CDC 2010). The rates of EOGBSD vary by continent according to the United Kingdom National Screening 
Committee (UK NSC; 2012). The lowest average rate of EOGBSD per 1,000 live births was reported in Southeast 
Asia (0.11) with higher rates reported in Africa (0.53), Europe (0.45), and the Americas (0.50). Internationally, 
there is variation in approaches to EOGBSD prevention. In some countries such as the United Kingdom, a risk-
based approach is used to determine candidates for intrapartum antibiotic prophylaxis (IAP) (UK NSC, 2012), 
whereas in other countries, prenatal screening and risk factors are combined to determine the need for IAP 
(Association of Ontario Midwives, 2010). 
 
Unintended Consequences of IAP 
Up to 30% of women in labor are exposed to IAP (Glasgow et al., 2005; Ohlsson & Shah, 2009), which changes 
their experiences of otherwise normal labor and birth (Hanson & VandeVusse, 2010). Intrapartum antibiotic 
prophylaxis is associated with unintended consequences for the woman, including an increased incidence of 
antibiotic resistance (Glasgow et al., 2005), allergic sensitization (McKeever et al., 2002), diarrhea (including 
Clostridium difficile) (de Vrese, 2009), and fungal infections (de Vrese, 2009). Neonates exposed to IAP have an 
increased incidence of Escherichia coli infections (Bizzarro, Dembry, Baltimore, & Gallagher, 2008; Glasgow et 
al., 2005), a greater risk of allergic sensitivity (Bedford Russell & Murch, 2006), and thrush (Ohlsson & Shah, 
2009). Further, neonates born to GBS positive mothers must be observed for 48 hours for signs of EOGBSD, 
resulting in longer lengths of stay (Balter et al., 2003; Buckler et al., 2010; Glasgow et al., 2007) with increased 
hospital costs (Buckler et al., 2010; Glasgow et al., 2007). 
 
The purpose of our quasi-experimental pilot study was to test the effect of oral prenatal probiotics against GBS 
colonization in pregnancy and evaluate the feasibility of a larger RCT. If prenatal probiotic exposure can be 
shown to reduce GBS colonization, then fewer women would require IAP and fewer fetuses would be exposed 
to adult doses of antibiotics shortly before birth. 
Methods 
A nonblinded, open-label, quasi-experimental design was approved by the Intitutional Review Boards of three 
institutions (two universities and the clinical research site). The study setting was a large clinical practice of 
certified nurse-midwives (subsequently referred to as midwife) serving a culturally and economically diverse 
urban population in the Midwest region of the United States. 
 
Participants  
Women self-selected to participate in screening and informed consent procedures done by the first two authors. 
The following inclusion criteria were used at study enrollment: low risk (no obstetric, fetal, medical or genetic 
risk factors), adult (≥18 years of age), pregnant at 28 ± 2 weeks gestation, able to speak and write English, and 
expressing willingness to particate in the study invervention (oral probiotic) and data collecion (vaginal and 
rectal swabs, questionnaires). 
 
A convenience sample of 20 healthy pregnant participants was sought. Following informed consent, the first 10 
participants were assigned to the experimental group. Nonrandom assignment was used to assure that the 10 
experimental group participants were enrolled. After enrolling the experimental group, the next 10 women were 
assigned to the control group. 
 
Intervention 
The study intervention consisted of one capsule of Florajen3 (previously described) orally each day. Florajen3 
meets the internationally established probiotic criteria (FAO/WHO, 2001). The probiotics contained in Florajen3 
are non-spore-forming, lactose- and hydrogen-peroxide-producing bacteria. The manufacturer recommends 
refrigeration to maintain maximum potency. As part of the preparation for this study, a sample of Florajen3 was 
left unrefrigerated for a period of 6 weeks and appropriate colony counts were sustained. Therefore for the 
purpose of the study, the participants in the experimental group were allowed to leave the probiotic 
unrefrigerated in an effort to improve daily compliance. Experimental group study participants were made 
aware of the probiotic brand used (open label) as the intervention. Further, the current state of knowledge 
about prenatal probiotics, including potentially rare side effects, were discussed at length using a 10-page 
informed consent document. The Florajen3 was placed in a study bottle equiped with an electronic cap 
monitoring sytem (MEMS) designed to record each time the bottle was opened by the participant. Each opening 
of the cap bottle equipped with this system is recorded on a microchip. The number of openings are retreivable 
via computer software when the bottle caps are returned. Researchers, midwives, and participants were aware 
of group assignment. The control group participants did not receive a placebo. 
 
Procedures 
Midwife prenatal care providers and staff were oriented to the study data collection procedures. Study data 
were collected at three points during routine prenatal visits with each participant's midwife (28 ± 2 weeks, 
32 ± 2 weeks, and 36 ± 2 weeks gestation). The study was considered completed at the 36 ± 2 weeks gestation 
visit. All participants received compensation at the completion of two study visits: $25 USD at 32 ± 2 weeks and 
$75 USD at 36 ± 2 weeks gestation. Probiotic group participants were offered a supply of probiotics for the 
remainder of pregnancy. 
 
Data collection measures and timing are summarized in Table 1. The midwife prenatal provider collected 
demographic information (birth date, race, and gestational age), and the vaginal and rectal swabs for GBS and 
wet mount, using accepted criteria to identify the vaginal pH and the presence of normal flora and/or pathogens 
(Donders, 1999). The wet mounts were examined microscopically by each midwife using standardized wet 
mount diagnostic procedures with normal saline and potassium hydroxide (Donders, 1999) and documented in a 
standard format. Participants completed a brief questionnarie (Table 2) at each study visit that asked them to 
describe yogurt ingestion, sexual activity (frequency and type), and vaginal cleansing practices (if used) in the 
past week; these were considered potential confounding variables. The participants were also asked if these 
practices were typical for them, and if not, how they were atypical. Women in the experimental group were 
asked to report any side effects that they attributed to the probiotics by notifying their midwife immediately, if 
necsessary, and then also noting the information on the study questionnaire. As part of routine prenatal care, 
the CDC-required GBS vaginal to rectal swab was collected by each participant's midwife and sent to the hospital 
laboratory between the 35- and 37-week visit. This was the only result that determined the need for IAP. 
 
Table 1. Data Collection Measures and Timing   
Timing   
Variable Measure 28±2 weeks 32±2 weeks 36±2 weeks 
Collection as part of routine 
prenatal care 
    
GBS colonization Vaginal to rectal swaba n/ab n/a Xc 
Study-specific collection     
GBS colony counts Vaginal and rectal swabs X X X 
Vaginal flora and pH Wet mount X X X  
pH 
   
 
Consistency 
   
 
Color 
   
 
Odor 
   
 
Lactobacillus to bacteria 
ratio 
   
 
Epithelial/leukocyte ratio 
   
 
Clue cells 
   
 
Bacterial vaginosis 
   
 
Trichomonas 
   
 
Yeast 
   
Intervention adherence Capsule count X X X  
MEMS® AARDEX® cap 
   
Note GBS = group B Streptococcus. 
a. This prenatal GBS screen was only done at 36± 2 weeks per CDC guidelines 
b. n/a = not applicable 
c. X = sample collection. 
 
Table 2. Dietary, Sexual, and Vaginal Hygiene Questionnaire  
Circle frequency        
Practices (of days during last 
week) 
       
Ate yogurt [brand________________] 0 1 2 3 4 5 6 7 
Took antibiotic 0 1 2 3 4 5 6 7 
Took a probiotic supplement besides “Florajen3” for 
study 
0 1 2 3 4 5 6 7 
Had sexual activity 
        
Penis to vagina intercourse 0 1 2 3 4 5 6 7 
Penis to anus intercourse 0 1 2 3 4 5 6 7 
Oral sex given to partner 0 1 2 3 4 5 6 7 
Oral sex received from partner 0 1 2 3 4 5 6 7 
Used a douche 0 1 2 3 4 5 6 7 
Cleaned inside your vagina with soap 0 1 2 3 4 5 6 7 
 
Researchers oversaw data collection and sample packaging. Participants were asked to return their probiotic 
bottles at each study visit and the Florajen3 capsules were replaced with a fresh supply. This gave the 
researchers the opportunity to notify the laboratory to record the date for later evaluation of the electronic cap 
monitoring results and conduct pill counts as an additional means to monitor women's responses to study 
participation, as well as probiotic adherence at each study visit. The vaginal and rectal swabs were placed on ice, 
packaged according to accepted procedures for human specimen handling, and shipped overnight to the 
laboratory of the final author, located 80 miles from the study site, for processing and analysis. 
Laboratory Analysis 
Upon receipt at the laboratory, the vaginal and rectal swabs were processed for quantitative colony counts of 
GBS. Polymerase chain reaction (PCR) was performed to determine whether bacteria isolated were the same as 
those in Florajen3. If positive for PCR, pulsed field gel electrophoresis (PFGE) would be performed to confirm the 
strain identity. These results were for research purposes only and were not available to the practicing midwives. 
 
The routine CDC-recommended prenatal GBS vaginal to rectal swabs were analyzed at the hospital laboratory, 
using a culture based method in which a threshold for GBS positive results is considered greater than 102 colony 
forming units (CFU) per swab. These results determined the need for IAP and were available to the midwives for 
management during labor. 
 
Statistical Analysis 
Demographics, the study variables, and laboratory data were entered into and analyzed with a statistical 
software package. Descriptive statistics, confidence intervals, chi-squareds, t tests, and correlations were used 
for analysis. Data were compared between participants at each study visit and between groups at each data 
collection point. The qualitative prenatal GBS culture results (positive or negative) from the hospital laboratory 
were compared to the quantitative vaginal and rectal GBS study results, adherence data, and confounding 
variables (yogurt ingestion, sexual activity, and vaginal cleansing practices). 
Results 
A flow diagram of study participants is presented in Figure 1, including enrollment, nonrandom allocation, group 
assignment, and those included in the final analysis. There were no screening failures from the healthy, low-risk 
prenatal midwifery caseload. Following enrollment, one experiemental group participant declined to continue 
because she said her family was not comfortable with her participation, two moved, and two were transferred 
to physician care. One of the transferees was diagnosed with gestational diabetes within a week of study 
enrollment and the other spontaneously delivered an otherwise healthy late preterm infant at 34-weeks 
gestation; therefore, neither completed the study. Only one woman in the control group declined to continue 
the study because she did not want to experience the required rectal swabs. 
 
 
 
Figure 1. Participant flow diagram. 
The potential of the probiotic intervention appears to be linked to daily adherence. 
 
Twenty cases were completed and analyzed (10 probiotic group and 10 controls). There were no adverse 
outcomes or negative side effects reported by any probiotic group participants. One half of the women who 
took probiotics spontaneously reported improved gastrointestinal symptoms. One woman reported that she did 
not have bacterial vaginoisis while taking the probiotic, which she stated had been a persistent problem for her. 
Participant demographic findings are presented in Table 3. There were no significant differences between 
groups for maternal age, gestational age at enrollment, or parity. 
 
Table 3. Participant Demographics  
Intervention group Control group 
 
 
Variable (n = 10) (n = 10) p Statistical test  
Mean (SD) Mean (SD) 
 
 
Age (years) 25.8 (3.8) 25.9 (5.1) .961 t test 
Gestational age (weeks) at enrollment 28.1 (1.6) 27.9 (0.8) .668 t test  
Number (%) Number (%) 
 
 
Race (n = 20) 
  
.165 t test 
African American (n = 10) 7 (35) 3 (15) 
 
 
Hispanic (n = 1) 0 1 (0.5) 
 
 
White (n = 9) 3 (15) 6 (30) 
 
 
Living Children (n = 20) 
  
.424 Pearson's 
Nulliparous (n = 6) 2 (10) 4 (20) 
 
Chi-squared 
Multiparous (n = 14) 8 (40) 6 (30) 
 
 
 
Vaginal and rectal GBS colony counts for each participant at each study visit are presented in Table 4. The study 
rectal cultures were positive in 11 women in both groups, whereas their vaginal swabs were negative. There 
were no significant differences (p .05) in GBS colony counts between probiotic and control group participants’ 
vaginal or rectal swabs at any of the three data collection points. Because GBS colonization at 35 to 37 weeks is 
clinically relevant, the qualitative prenatal and the quantitative study laboratory results at this gestation are also 
presented in Table 4 for comparison. Two participants in each group had positive prenatal GBS culture results. 
The two probiotic group participants had lower colony counts (2 × 102 CFU) on the quantitative cultures than the 
two control group participants (7 × 102 CFU and 2.07 × 105 CFU). One participant in each group was negative on 
the prenatal culture despite measurable GBS on a study swab. There were no significant differences (p .05) in 
GBS results based on group assignment, vaginal pH, or wet mount results. 
 
Table 4. Quantitative GBS Results in Colony Counts at Three Study Visits Compared with 36±2 Weeks Qualitative 
GBS Prenatal Culture   
28±2 weeks 
 
32 ±2 
 
36 ±2  
 
  
(study 
baseline) 
 weeks  weeks  
 
Study Subject 
      
36 ±2 weeks 
qualitative 
group number Vaginal Rectal Vaginal Rectal Vaginal Rectal prenatal culture 
Probiotic 1 
      
*  
2 
       
 
3 
       
 
4 1.0 x103 2.0 x104 
 
2.0 x102 
 
2.0 x102 Positive  
5 
       
 
6 
  
2.0 
x105 
 
2.0 
x105 
 
Positive 
 
7 
       
 
8 
 
1.63 
x105 
 
3.5 x105 
 
3.5 x105 
 
 
9 
       
 
10 
       
Control 11 
       
 
12 5.5 x104 3.3 x104 
 
7.0 x102 
 
7.0 x102 Positive  
13 
       
 
14 
       
 
15 
       
 
16 
       
 
17 3.4 x104 9.0 x102 
 
2.07 
x105 
 
2.07 
x105 
Positive 
 
18 
  
7.0 
x102 
 
7.0 
x102 
  
 
19 
   
1.6 x104 
 
1.6 x104 
 
 
20 
       
Note: * Blank cell = Negative at 102 Colony Forming Units/Swab 
 
Analyses using PCR were performed on 117 isolates from the 10 participants who took the probiotic. Of those, 
four tested positive for at least one of the bacteria contained in Florajen3. One of the bacterial strains contained 
in Florajen3 (B. lactis) was identified by PCR and PFGE in the rectal specimen of one experimental group 
participant, indicating that the probiotic survived the gastrointestinal tract in this case. None of the Florajen3 
probiotic strains was detected in the vaginal specimens. Details of laboratory methods are presented online as 
supplemental materials in an appendix. 
 
The MEMS cap data were not statistically analyzed due to multiple problems with data retrieval, including lost or 
destroyed caps. Therefore, pill counts were the only usable adherence measure. Pill counts were compared 
between GBS positive (n = 2) and negative (n = 8) participants in the probiotic group. The two participants who 
were GBS positive averaged 68% probiotic adherence based on pill counts, whereas the eight who remained GBS 
negative had a 90% adherence rate (p   .05). 
 
Confounding variables were examined for their effect on GBS colonization independent of study group 
assignment. There were no significant differences (p  .05) in GBS results on any confounding variables collected 
on the questionnaire (Table 2), except yogurt ingestion. Women who consumed yogurt were significantly more 
likely to be GBS negative (p = .02). Yogurt ingestion ranged from 0 to 9 times per week at the three data 
collection points. One half of the participants indicated that they typically consumed no yogurt. Of those who 
ingested yogurt, the average frequency was 2.3 times per week. There were no patterns in specific brands 
consumed. 
 
Several nonsignificant trends (p  .05) were noted. Women who had higher rates of GBS also more frequently 
reported participating in oral sex (given or received) and ingesting prenatal antibiotics. Vaginal cleansing 
practices were unrelated to GBS findings. Only a few women in either group reported douching (none in the 
experimental group and two in the control). However, a total of five women in each group reported at one or 
more study visits cleaning inside the vagina with soap during the prior week. This practice increased in frequency 
among the participants in the experimental group whereas it was reported less often in the control group over 
time. 
Discussion 
Florajen3 inhibited GBS in vitro (Ephraim et al., 2012), and our findings suggest that it has a suppresive effect in 
vivo. Seven participants in the probiotic group and six controls remained negative for GBS at all three study 
visits. Three of the four participants who were positive on the qualitative 36-week prenatal GBS culture had 
detectable GBS colony counts at baseline and the two subsequent data collection points. Due to financial 
constraints and the small sample size, this study was not statistically powered to demonstrate a significant 
reduction in prenatal GBS infections. However, in this small sample, probiotic group participants had lower GBS 
colony counts compared to controls. Although these findings are hopeful, a RCT with a larger sample is needed 
to demonstrate that third trimester probiotics inhibit GBS colonization. 
 
The findings of a recent integrative review indicated that in 23 of 35 studies (66%) of prenatal probiotics, the 
intervention was initiated during the third trimester (VandeVusse et al., 2013). It is unknown if earlier probiotic 
administration is necessary to inhibit GBS colonization at the clinically important testing point of 35- to 37-weeks 
gestation (CDC, 2010). This study demonstrated the feasibility of a larger RCT using the same population and 
study procedures. In a larger trial, more detailed analysis of Lactobacillus species would allow for better 
comparisons of between group differences to aid in clarifying the mechanisms of action of probiotics against 
GBS in vivo. 
Confounding Variables 
The effect of vaginal cleansing practices on GBS is unknown. There is a direct association between douching and 
vaginitis (Cottrell, 2010). However, consistent with the collective advice of the midwife providers against 
douching, this practice was reported by only 10% of the participants. In addition, more then one half of the 
women in each group reported at one or more study visits that they cleaned inside the vagina with soap during 
the prior week. This practice is not well understood and needs further study for its possible impact on vaginal 
flora and GBS. 
 
The association between sexual activity and vaginal flora has been studied with mixed results. Antonio, Meyn, 
Murray, Busse, and Hillier (2009) found that nonpregnant women who reported participating in unprotected 
sexual intercourse during the past week were less likely to be colonized with vaginal Lactobacillus. Newton, 
Butler, and Shain (1996) found that specific sexual practices were not predictors of GBS colonization. In fact, 
women who reported anal intercourse were found to have lower rates of GBS. However, women who reported 
more than one sexual partner in the prior month had higher rates of heavy GBS colonization. The relationship 
between sexual practices on Lactobacillus and GBS colonization needs more study. 
 
A significant inverse relationship between yogurt ingestion and GBS colonization at 36-weeks gestation was 
identified. The ingestion of cultured milk products in the United States of America is increasing. However, the 
diversity of brands, the variability of probiotic bacterial species and colony counts, and the limits of dietary recall 
make controlling this confounder a challenge in future research. 
 
The amount of active probiotic bacteria ingested daily appears to be an important consideration (VandeVusse 
et al., 2013). Two prospective cohort studies were conducted in Norway to explore the impact of prenatal 
consumption of probiotic cultured milk products (Biola and Cultura) on two perinatal complications. The intake 
of probiotic milk products was associated with reduced risks of preeclampsia and spontaneous preterm delivery, 
respectively (Brantsaeter et al., 2011; Myhre et al., 2011). Dosage was estimated by food frequency 
questionnaires and categorized (differently in each study) as zero, low, and high intake. The mean high intake 
combined from the two studies resulted in an average consumption of 138 ml per day, equivalent to 109 CFU of 
Lactobacillus and Bifidobacterium. In comparison, the probiotic supplement used in this study (Florajen3) 
represented a 15 times higher dose of active probiotics. The optimal dosing of prenatal probiotics has not been 
determined and needs further scientific investigation. 
 
Adherence 
The potential of the probiotic interventon appears to be linked to daily ingestion. The MEMS caps were used 
with the participants in the probiotics group to record adherence. Unfortunately, data from one half of the 
MEMS caps were not usable and therefore were not analyzed (two were never returned by participants who 
moved away). Therefore, adherence was measured indirectly by the use of pill counts. This was a less accurate 
means of determining how much probiotic was injested between study visits. Overall, probiotic adherence 
averaged 86%, indicating that prenatal participants can be expected to follow the study protocol. 
 
Limitations 
This study has additional limitations. The findings are not generalizable due to the small sample size that did not 
allow for the detection of differences between groups on the dependent variable. The prenatal GBS results were 
analyzed using the culture based method and the study swabs were analyzed using the more sensitive PCR 
method. Laboratory recovery of bacterial species contained in the probiotic could have been limited by 
variations in probiotic adherence between subjects, overnight shipping of the samples, and the amount of fecal 
material present on the swabs. It was difficult to demonstrate that probiotic ingestion could be verified by 
culture and molecular methods. Sample collection was done by the midwife prenatal care providers and there 
may have been differences in swab techniques despite study protocol orientation. 
 
A larger, prospective, double blind, placebo controlled trial is feasible in a midwifery practice that serves a 
diverse population. 
 
Absence of Side Effects 
Women in the intervention group reported no side effects related to the Florajen3 intervention. The finding that 
one half of the women who consumed the probiotic reported improved gastrointestinal symptoms stimulated 
pilot testing of a revised symptom tool for future research. 
 
Future Research 
The study was not powered to examine the efficacy of the probiotic intervention against GBS colonization. Given 
that a 20% GBS rate was documented in this study, a sample size of 440 would be needed to demonstrate a 
reduction in GBS colonization from 20% to 10% at 36-weeks gestation. Patient-collected GBS swabs yield similar 
colonization rates compared to those collected by providers, but self collection may be more acceptable to 
women (Arya, Cryan, O'Sullivan, Greene, & Higgins, 2008; Mercer, Taylor, Fricke, Baselski, & Sibai, 1995). Self-
collection of vaginal and rectal samples and wet mounts could possibly improve participation and study 
continuation in future research. Because adherence is an important issue, the use of MEMs caps should be 
considered in future studies. However more efforts to assure return of the caps should be instituted. In a larger 
RCT of prenatal probiotics, any impact of potential confounding variables (yogurt ingestion, sexual activity, and 
vaginal cleansing practices) on GBS colonization would be expected to be equivalent between groups. 
Conclusion 
This is the first published study of prenatal probiotics conducted in the United States. Because GBS is an issue for 
childbearing women worldwide, more research on clinical interventions to prevent colonization before birth is 
needed. This study demonstrates that a larger prospective double blind placebo controlled trial is feasible in a 
midwifery practice that serves a diverse population. 
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Supporting Information 
Appendix: Molecular Methods 
Polymerase Chain Reaction (PCR) Methods 
Polymerase chain reaction was performed using methods developed by DuPont Nutrition and Health group.  
DNA was extracted using heat lysis (1-2 colonies picked to 50 µL nuclease free water and boiled for 10 minutes).  
PCR reactions specific for each species of bacteria were run.   
 
Primers were obtained from IDT DNA. The reaction mixture consisted of  17.4 µL nuclease free water, 2.5 µL 
buffer, 2 µL dNTPs, and 0.125 µL Taq. Then 1 µL each primer (20 µM) and 1µL DNA was added.  The running 
conditions were: 7 min at 95ºC, followed by 30 cycles of 95ºC for 30 seconds, annealing (see Table 1) for 30 
seconds and 72ºC for 30 seconds, followed by a 5 minute 72ºC  cycle for final extension.  Product DNA was 
amplified using the Applied Biosystems 2720 Thermal Cycler and detected on a 1.2% FlashGel. 
 
Table 1.  Primers and running conditions 
Organism Primers (forward and reverse) Annealing temperature (˚C) 
L. acidophilus 5’-GGTTGGGGAAATGCAAACTAAAGA-3’ 
5’-AAAGTGCACAAAACTAGCACCTTT-3’ 
56 
B. lactis 5’-GCACCGCGGCGTGGAAGAA-3’ 
5’-AGGTTGACCTCATCGGCGAGCTCT-3’ 
63 
B. longum 5’-TACGAAGCTCTGAAGCCGTACGCT-3’ 
5’-CCTTCTGAGCCTCGTCGCCCT-3’ 
63 
 
Pulsed Field Gel Electrophoresis (PFGE) Methods 
Isolates were grown for 48 - 72 hours in MRS broth supplemented with 0.05% cysteine or pre-reduced BHI 
broth.  400 µL of cell suspension was transferred to a 1.5 mL microcentrifuge tube which was centrifuged at 
approximately 13000 x g for 3 minutes.  The supernatant was removed and the pellet was resuspended in 300 
µL TE. PFGE plugs were then prepared according to a previously published method (Halpin, Garrett, Ribot, 
Graves, & Cooper, 2010) with the following alterations:  15 µL of proteinase K and 300 µL 1.8% SeaKem Gold 
agarose without 1% sodium dodecyl sulfate.  Plugs were incubated overnight in a 55˚C water bath.  The 
restriction digest was performed as previously described (Ribot et al, 2006).  PFGE was performed on the 
BioRad Genepath, program 13, with switch times of 1-23 seconds, non-linear, 6V/cm, run angle of 120º for 18.5 
hours. 
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